Explore This Program

Overview

The New England Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) Group is a nation-wide, collaborative effort that conducts high-quality, multi-site clinical trials to improve the outcomes for patients with a range of emergency conditions.

The New England Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) Group is a nation-wide, collaborative effort that conducts high-quality, multi-site clinical trials to improve the outcomes for patients with a range of emergency conditions. In collaboration with partners across New England, we will both lead and participate in large scale definitive phase III trials for conditions such as traumatic brain injury, cardiac arrest, and others. Upcoming SIREN research studies aim to improve care for patients with traumatic brain injuries and cardiac arrests. The SIREN network will lead the next generation of definitive emergency care trials.

New England SIREN Members

Current Studies

ESETT - The Established Status Epilepticus Treatment Trial
ESETT is aiming to determine which of 3 FDA approved medications is the best for treating emergency seizures that do not stop, a condition known as status epilepticus. Patients will receive either fos-phenytoin (also known as Cerebyx, or Prodilantin), valproic acid (also known as Depakote), or levetiracetam (also known as Keppra). ESETT will use a special set of rules called Exception From Informed Consent (EFIC) for emergency research. Study-wide ESETT Enrollment for adults aged 18 years and above has been closed, meanwhile the enrollment for children between ages 2 and under 18 will be continued until the enrollment target is met.

If you would like to "opt out" or make sure your child is not enrolled in this trial, please click here or contact us at SIREN@partners.org.

You can also visit the ESETT national study website for more information.

Upcoming Studies

BOOST-3 – Brain Oxygen Optimization in Severe TBI Phase 3 Trial
BOOST-3 proposes to determine whether a treatment protocol based on brain tissue oxygen monitoring improves neurologic outcome in this most severely injured group of patients as compared to the standard care of intracranial pressure monitoring only. The trial plans to enroll 1094 subjects.

The article published based on the BOOST phase 2 trial can be found here.

You can also visit the BOOST-3 national study website for more information.

ICECAP – Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients
ICECAP proposes to determine if identifying an optimal duration of cooling can improve outcomes in comatose adult survivors of cardiac arrest, and if development of a duration response curve can substantiate efficacy in a wider patient population. The trial plans to enroll 1800 subjects.

You can also visit the ICECAP national study website for more information.

HOBIT – Hyperbaric Oxygen Brain Injury Treatment Trial
There continues to be an overarching problem of high mortality and poor outcome for victims of severe traumatic brain injury (TBI). Preclinical and clinical investigations indicate that hyperbaric oxygen (HBO2) has a positive impact on reducing brain injury and improving outcomes in severe TBI. By markedly increasing oxygen (O2) delivery to the traumatized brain, HBO2 can reverse the lack of O2 that precipitates cellular energy failure and subsequent brain cell death.

HOBIT proposes to determine the most effective combination of HBO2 treatment parameters (e.g., pressure, frequency, etc.) and HBO2 dose schedule without producing O2 toxicity and clinical complications that are most likely to demonstrate improvement in the outcome of TBI patients. This trial will provide important data and information to plan a definitive phase III efficacy trial. The HOBIT trial plans to enroll 200 subjects.

You can also visit the HOBIT national study website for more information.